Enzyme News and Research

RSS

CNIO and HKUST researchers identify how some gliomas acquire chemoresistance

A team led by Massimo Squatrito, Head of the Seve Ballesteros Foundation Brain Tumour Group at the Spanish National Cancer Research Centre, have made important findings of how some gliomas can acquire chemoresistance.

4 Aug 2020

Specifically designed cyclic peptide inhibitor shown to be active against SARS-CoV-2

A new bioRxiv study by a research group from the University of California Irvine shows in vitro activity and non-toxicity of the first-in-class cyclic peptide that inhibits the main protease of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – laying the groundwork for its use in the treatment of coronavirus disease (COVID-19).

4 Aug 2020

Novel mutation identified in SARS-CoV-2 spike protein from Sweden

Researchers from Sweden and Brazil have identified a novel mutation in a strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) obtained from a patient in Stockholm, Sweden, in late April.

4 Aug 2020

Normal DNA repair process can lead to mutations in cancer

Hypermutation is an unusual occurence that can lead to many nearby mutations at once, severely damaging our genetic material and potentially causing cancer.

4 Aug 2020

Researchers achieve bleeding-free anti-coagulation with synthetic inhibitor

Patients who suffer from thrombosis, pulmonary embolism or stroke are usually put on drugs that help their blood flow more smoothly through their body.

4 Aug 2020

Researchers initiate multiple studies to identify coronavirus-related heart problems

COVID-19 is shown to impact the heart and, in some cases, have long-lasting cardiac effects. To discover the extent to which COVID-19 affects the heart, cardiologists and researchers with the University of Miami Miller School of Medicine have begun multiple studies.

4 Aug 2020

ALKBH5 enzyme shows promising target for cancer immunotherapy

Cancer immunotherapy - a treatment that better enables a patient's own immune system to attack tumors - has shown great potential against some cancers. Yet immunotherapy doesn't work against all tumor types, and many patients who initially respond later develop resistance and relapse.

4 Aug 2020

Zika virus mutation responsible for quick spread, birth defects uncovered

A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.

3 Aug 2020

Study shows high SARS-CoV-2 seroprevalence, but low death rate in Malawi's health care workers

A study by researchers from Malawi and United Kingdom reveals a significant discrepancy between predicted coronavirus disease (COVID-19) mortality in the observed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence rates in health care workers and reported deaths in urban Malawi in southeastern Africa, indicating early exposure, but a slow progression of the outbreak. Their findings are currently available on the medRxiv preprint server.

3 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

Novel short ACE2 isoform may influence SARS-CoV-2 susceptibility

A study led by researchers at the University of Southampton, UK, has identified a novel short isoform of the full-length receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain entry to host cells.

3 Aug 2020

Meningitis case at Children's National Hospital raises concerns about antibiotic resistance

A recent meningitis case at Children's National Hospital raises serious concerns about antibiotic resistance in the common bacterium that caused it, researchers from the hospital write in a case report.

3 Aug 2020

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on its ability to infect new host cells following its replication and release from infected cells. This pivots on its ability to bind to cell surface receptors like the ACE2 enzyme.

3 Aug 2020

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020